Blood Coagulation and the Biochemist
R. G. MACFARLANE My own interest at this time was the immensely powerful coagulant action of the venom of Russell's Viper. It had no action on fibrinogen, so it was not like thrombin; it required calcium for its action, and presumably, like thromboplastin, it acted on prothrombin. But whereas the best tissue thromboplastins were a sort of thick soup which defied any attempt at purification, the venom was active at concentrations of the order of I microgram per 100 ml. of blood. It seemed likely, therefore, to be an enzyme. Like tissue thromboplastin, its action seemed to involve a lipid. Trevan and I found that crude lecithin greatly potentiated the action of the venom, and conversely, that the removal of most of the lipid from plasma by certifuging or extraction prevented its coagulation by the venom, though the activity could be restored by adding lecithin or the fat extracted. King was interested in these results, and gave me a number of pure phospholipid samples some of which he had prepared himself. We found, to our surprise, that pure lecithin was inactive, but a sample of this which had been exposed to air for some time and had acquired a rich brown colour was active with the venom, and presumably as a result of oxidation. We made many attempts to discover what the venom did to crude lecithin, and what the venom lecithin mixture did to the blood clotting mechanism. I was working on the theory that .. tissue thromboplastin" was a mixture of a venom-like enzyme, and a phospholipid cofactor, but, though one could extract a water soluble coagulant factor from lung tissue, it was not much potentiated by crude lecithin. I did, however, extract something very like the venom J,
Fibrinogen -------~Fibrin was supposed to be released by damaged tissue and it was supposed to act on prothrombin in the presence of calcium to form thrombin, which then converted fibrinogen into fibrin. Biochemically, the situation was not very promising; fibrinogen had been partially purified, and was known to be a high molecular weight plasma protein. Some people believed that thrombin was an enzyme, which made prothrombin a proenzyme, but there was no proof of this, and it was not generally accepted. About the nature and action of thromboplastin there was conflict and confusion. MeIIanby (I963), who supported the view that thrombin was an enzyme considered that thromboplastin was a kinase, but the RADCLIFFE INFIRMARY, OXFORD I first came to know Earl King in 1937, at the majority of workers believed that the active Post Graduate School. He, of course, was principle was probably a phospholipid, and the already a famous biochemist, and I was a most main biochemical approach was the attempt to junior pathologist dabbling in research on blood concentrate and identify this. But, though some coagulation. I do not think that he approved of believed that the active principle was lecithin and the subject, it was too vague for a good bio-others that it was cephalin, it was significant that chemist and little could be done in the way of all attempts at purification resulted in loss of identification, measurement, and kinetics. At activity. But the most striking thing about that time, the theory of clotting was simple, but current theories of coagulation was that they it failed to explain the facts; later, of course, the failed to explain such facts of real life, as the nontheory became far more complicated and still coagulation of haemophilic blood, or of blood did not explain the facts, so perhaps we were collected in paraffin coated vessels, or the better off then than we realised. In those days, coagulation of blood without thromboplastin there were just four recognised clotting factors, after contact with glass. prothrombin, fibrinogen, calcium, and something called thromboplastin (Fig. 1) . Thromboplastin from human saliva, not so surprising, perhaps when one considers that the venom is really a modified saliva. But none of these effects were explained, and the war put a stop to academic persuits of this sort.
The first few years after the war produced a remarkable proliferation of clotting factors. The cause of this was the wide use of two tests which had been developed for routine diagnostic purposes, and which were based on the idea that prothrombin was simply converted by thromboplastin. The first test was the so-called one stage prothrombin time test of Quick (1935) , in which brain extract is added to blood and the clotting time (normally 12-15 seconds) recorded.
In the presence of excess thromboplastin and adequate calcium and fibrinogen, the clotting time should, by the four-factor theory, be dependant only on the concentration of prothrombin. But in practice a long" prothrombin time" was observed in a number of cases despite a normal amount of prothrombin, and the investigation of this phenomenon led to the discovery, by Owren in 1947, of an additional factor required for the activation of prothrombin, which he called Factor V. Shortly afterwards, Factor VII was discovered, also required for the activation of prothrombin by thromboplastin, the term "factor VI" having already been used in another context. Then it was discovered that Factor X was also required, so we had at least 5 factors concerned with the activation of prothrombin; thromboplastin, Factors V, VII and X and calcium; and there was a suspicion, at least in my mind, that thromboplastin itself was a complex of more than one factor and consisted of" tissue factor" and a phospholipid ( The next phase was a shift of attention to the clotting of blood after contact with a foreign surface, a phenomenon demonstrated by Lister in 1863, and then neglected. After surface contact, blood does clot quite effectively, without added thromboplastin, but it fails to do so in a number of naturally occuring clotting defects, including haemophilia. We thought that " thromboplastin" must be generated by the blood itself (Biggs, Douglas and Macfarlane 1953) , and the so-called thromboplastin generation test was devised to study the process (Biggs and Douglas 1953) . But it was found that the process differed from prothrombin activation by tissue factor, since Factor VII was not required. Moreover, it was discovered that several other new factors were needed if contact activation was to be effective, and which were not needed by tissue thromboplastin. One of these is Antihaemophilic globulin, or Factor VIII, lack of which is the cause of haemophilia, and study of other haemophilia-like conditions led to the discovery of Factor IX, lacking in Christmas disease, Factor X (or Stuart Prower Factor), Factor XI (or PTA) and Hageman Factor, or Factor XII. An International Committee was set up to deal with the hopelessly confused terminology which developed, and this laid down the Roman Numeral nomenclature which is used here.
So 8 factors are concerned with the activation of prothrombin, and if we put the two systems together (Fig. 3) , it will be seen that Factors Y, X, and calcium are common to both the tissue or extrinsic system, and the contact, or intrinsic system. This welter of factors did not make the clotting mechanism any simpler to understand, and endless experiments have been done, and theories propounded on the ways in which they may react together. Some still believe that most of these factors are "accellerators" or catalysts for a fundamentally simple conversion of prothrombin to thrombin, but most workers believe that they probably react in sequence, and many different sequences have been proposed. If we confine ourselves to the contact system, evidence has gradually accumulated to suggest that the sequence is in the order: contact-XII-XI-IX-VIII-X-V-prothrombin.
The first thing that a biochemist would ask, after having said" I don't believe it " is probably " what are these clotting factors, and what do they do?" All the evidence suggests that the clotting factors, except phospholipid and calcium, are proteins. They can be separated by such methods as differential precipitation, absorption, or electrophoresis. Fibrinogen, prothrombin, and Factor X have been purified to an extent that allows estimation of molecular weight, and there is information on the physical properties of the others. Roughly, one can group fibrinogen, Factor V and Factor VIII together in being labile, large molecular weight proteins which are not absorbed by inorganic gels. The other group consists of prothrombin, and Factor VII, IX, and X, which are relatively stable, and are all absorbed by inorganic gels, and dependant on Vitamin K for their synthesis in vivo.
As to what these factors do, how they react in the clotting mechanism, I think that, after many years of confusion, the position is beginning to be clarified. The first interaction to be established was that between thrombin and fibrinogen. As you know, it has been shown conclusively that thrombin is a specific proteolytic enzyme and an esterase. It splits off a part of the fibrinogen molecule, the so-called fibrinopeptide, and the remaining portions of the fibrinogen molecules then polymerise to form fibrin. So prothrombin is a proenzyme. There is a good deal of evidence that the activation of prothrombin is also proteolytic; the molecular weight of thrombin is less than that of pro thrombin, prothrombin can be activated by known proteolytic enzymes, and its normal activation is prevented by inhibitors of proteolysis. It is probable, therefore, that the natural activator of prothrombin is, like thrombin, a specific proteolytic enzyme. But where does it come from? I think that this question may have been clarified by returning to more recent work on Russell's Viper venom. When we left it, the venom seemed capable of activating prothrombin, but required the presence of phospholipid and calcium to do so. It was later shown that it also needed Factor V and Factor X. So we have a mixture of venom, phospholipid, Factor V and Factor X which, between them produce prothrombin activator. But which reacts with which? complicated a story to present here. Essentially it has been shown that if Factor X is activated by anyone of these systems, it cannot be further activated by the other . The conclusion is that Factor X, like prothrombin, is a pro-enzyme, and that it is itself or ussell's Viper Venom <c-(XII + XI + IX + VIII)
activated by enzymatic splitting of its molecule Evidence is coming in that most of the other factors seem to behave in the same way. As they exist in the plasma, they are inert, but they can be activated to produce a derivative, probably an enzyme, which activates the next stage. Starting with surface contact, Factor XII is activated, probably by an unfolding of its molecule as a result of its adsorption to surfaces such as glass or tissues other than vascular endothelium New techniques allow one to work with relatively pure preparations of these factors, so that it is possible to incubate various combinations of two or more, and then by adding the rest to see ifthe preincubated mixture has reacted. The venom is antigenic, and a highly potent specific venom antiserum can be prepared, which will destroy venom activity in a few seconds, but not affect the other clotting factors. So one can easily see if the venom reacts with any particular factor, by incubating the venom-clotting factor mixture, and then adding antivenom. If a new product has been formed, its activity will not be affected by the antiserum, but if nothing has happened, since the antiserum will destroy the venom the addition of the remaining factors will result in no prothrombin activation (Fig. 4) . It will be seen than the venom reacts with Factor X, and not with the other factors or phospholipid, and that it is the product of this reaction between venom and X which then reacts with Factor V and phospholipid to activate prothrombin (Macfarlane 1961) . Esnouf and Williams (1962) extended this work by showing that the venom contains an enzyme which splits the Factor X molecule to form a derivative which has esterase activity.
It is this active product which has the coagulant effect, and it is itself an enzyme.
But how does this work help to clarify physiological clotting? Factor X is required both by the contact system and the tissue system of the clotting mechanism. If it were possible to show that it was activated in the same way by these two systems as it is by Russell's Viper venom, then we shall have shown that a probably enzymatic activator of Factor X is produced during normal clotting (Fig. 5) . I think we have been able to show this, but it is too long and Surface Contact Ĩ Fig. 6 -The pro-enzyme enzyme sequence of the contact-activated clotting system. The letter A indicates the active (enzyme) form of the factor concerned, with the exception of IA (fibrin.) (Margolis 1963) . Activated Factor XII then activates XI, which activates IX. We have recently been able to show that activated IX activates VIII which activates X (Macfarlane, Biggs, Denson and Ash 1964) . If as suggested by Dr. Esnouf we use the letter A to denote an active product, then the whole clotting sequence from surface contact to fibrin formation can be set out quite simply (Fig. 6 ). There is fairly good evidence for every stage shown except the activation of Factor V, but I have included it in the sequence for the sake of completeness. I should point out that Factor X can also be activated by tissue factor plus factor VII, and also, of course, by Russell's Viper venom. Phospholipid seems to be required for the activation of prothrombin itself, and probably, also at the stage of the activation of VIII.
It seems most likely that the phospholipid presents a surface to which the reacting factors are absorbed, thus functioning as a catalyst. Perhaps the most striking thing about this system is the rapidity with which the active products are destroyed in the blood or serum. Within a few minutes of clotting, none can be demonstrated in the serum, which then only contains the unconsumed portions of the original plasma content of Factors IX, X, and VII. At every stage, therefore, the rate of activation has to exceed the rate of destruction if a level sufficient to activate the next stage is to be reached. Seegers (1962) gives figures to show that the average life span ofa thrombin molecule is 24 seconds, and the other activated factors may be even more short lived. That is why their existence has remained undiscovered for so long.
The most obvious objection of reasonable people to this scheme is that it seems so unnecessarily complicated. Why should so many enzymes be involved simply to clot fibrinogen? I think the answer will become apparent if we consider the amounts of the products involved and the rate of their production. Normal clotting causes the transformation of about 2-300 milligrams per 100 ml of plasma of fibrinogen into fibrin. This does not happen for some minutes, but when it does it happens quite suddenly, and fibrin formation is complete in a few seconds. This reaction is produced by the sudden almost explosive appearance ofthrombin. Any more gradual generation is haemostatically ineffective, as for example in haemophilic patients whose clotting time is normal, but in whom fibrin formation though it begins at the normal time, is not quickly completed.
The amount of thrombin produced in this sudden generation is about 15 milligrams per 100 ml of plasma. We have no figures for Factor V, but this 20 milligrams of thrombin is released by the activation of less than 2 milligrams of Factor X, less than 200 ILg of Factor VIII and much less than this of Factor IX. At each stage, too the rate of the reaction increases as the sequence progresses.
(1 ) I think it is quite clear that this is a biochemical amplifier, with a gain in both amount and rate of activation at each stage. If the gain is ten fold at each stage, then the overall gain is 1 x 10 6 in the whole cascade. There are seven stages because this amount of gain is necessary to transform the minute signal of surface contact into the final and considerable explosion of enzymatic activity, just as seven transistors are needed to receive Radio Luxemburg in Oxford.
One could speculate on positive and negative feed back mechanisms, and on the mechanism of evolution of such a system, which has similarities to fibrinolysis, the activation of kinins and peptides, the complement system, and other complex blood mechanisms. I think one might see how, as more efficient haemostasis was required by higher animals with greater blood pressures and activity, extra stages could be plugged-in, so to speak, between existing stages The other aspect of great interest are the safeguards which prevent this system getting out of hand and causing general thrombosis instead of local haemostasis. The rapid destruction of active factors is one such safeguard. It is likely also, that, as soon as thrombin rises to a concentration sufficient to attack fibrinogen, it also destroys factors VIII and V thus switching off the whole mechanism. Fig. 7 -Diagram illustrating an interpretationof the data of Ferguson and Ennis (1963) . Prothrombin is activated directly by trypsin, but more effectively by Fac!or X which has been activated by the same concentration of trypsin. This illustrates the" amplification" achieved by an additional stage, and suggests a mode of evolution of such stages. and thus provide greater activity. It can be shown, for example, that trypsin, which will activate prothrombin directly, is far more effective as a coagulant if Factor X is also present, as shown in Fig. 7 (Ferguson and Ennis 1963) . In such an experiment, one might suppose that Factor X acts as a competitive substrate, and the product of its reaction wit~tryp~in .is more effective than trypsin Itself in activatmg prothrombin. It may be, therefore, that extra stages have evolved by the adaptation and natural selection of alternative substrate proenzymes.
